June 11, 2025

Simvastatin Lowers Cholesterol—but Does Not Improve Depression Symptoms

A randomized trial of 160 adults with depression and obesity found no improvement in mood symptoms from adding simvastatin to escitalopram, though the statin significantly lowered cholesterol and inflammation levels.

Conexiant

June 05, 2025

Depression at Any Age Linked to Dementia: Study

A large research review found that depression diagnosed in either midlife or late life was linked to a significantly higher risk of developing dementia.

Conexiant

June 05, 2025

Conservative Mental Health Study Faces Retraction

Scandinavian Journal of Psychology retracts study on conservatism and mental health, citing methodological flaws and biased language despite authors' objections.

Conexiant

June 05, 2025

Sister’s History Tied to 10-Fold Increase in Postpartum Psychosis Risk

A population-based study discussed at APAAM25 links full sibling history to increased risk of postpartum psychosis – but notes the absolute risk remains low.

Conexiant

June 04, 2025

Restrictive Eating Tied to Depression in Men

A UK study found that dietary restraint is linked to higher depressive symptoms, with stronger effects seen in men and individuals with elevated BMI.

Conexiant

May 29, 2025

New Dental Floss Can Track Stress Levels in Minutes

The platform consistently detected cortisol changes corresponding to stress exposure, matching the accuracy of laboratory-based analysis.

Conexiant

May 29, 2025

Physical Disease Clusters Predict Future Depression Risk

A large UK study found that people with multiple physical health conditions face a significantly higher risk of developing depression, with risk levels varying by type and number of conditions.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 28, 2025

Fremanezumab Cuts Migraine, Depression Burden in Trial

Fremanezumab reduced monthly migraine days and improved depression scores compared with placebo.

Conexiant